AMPH
Amphastar PNASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Small-Cap Blend
$28.49+3.00%
Close Nov 6, 2026
- Market cap
- $1.26B
- 1 month
- +10.4%
- 3 months
- +40.3%
- 1 year
- +12.6%
- 52-week range
- $16.87$29.40
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- $0.86Quarter to Sep 30, 2026 · 7 analysts · revenue $197.5M · -0.7% in 30d
- Short interest
- 13.8% of float4.3M shares · settled Oct 15, 2026 · -1.6% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $730.02M
- Net income
- $78.55M
- Free cash flow
- $152.89M
- Book value
- $768.16M
- Total debt
- $688.32M
- P/E
- 16×
- Price / sales
- 1.7×
- Price / book
- 1.6×
- FCF yield
- +12.2%
- Net margin
- +10.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
Read more
It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Website
- amphastar.com
- Headquarters
- Rancho Cucamonga, CA, United States
- Employees
- 1,976
- Listed
- Jun 25, 2014
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 25, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $183.9M | +5.4% | 50.8% | $39.7M | $30.3M |
| Mar 2026filed May 7, 2026 | $171.2M | +0.4% | 41.1% | $13.6M | $6.4M |
| Dec 2025filed Feb 26, 2026 | $183.1M | -1.8% | 46.8% | $35.6M | $24.4M |
| Sep 2025filed Nov 6, 2025 | $191.8M | +1.6% | 51.4% | $25.3M | $17.4M |
| Jun 2025filed Aug 7, 2025 | $174.4M | -4.4% | 49.6% | $42.2M | $31.0M |
| Mar 2025filed May 8, 2025 | $170.5M | -0.8% | 50.0% | $37.3M | $25.3M |
| Dec 2024filed Mar 3, 2025 | $186.5M | +4.7% | 46.5% | $45.1M | $38.0M |
| Sep 2024filed Nov 7, 2024 | $188.8M | +4.6% | 54.0% | $57.0M | $40.4M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 26, 2026 | $719.9M | -1.7% | 49.5% | $140.4M | $98.1M |
| Dec 2024filed Mar 3, 2025 | $732.0M | +13.6% | 51.1% | $205.4M | $159.5M |
| Dec 2023filed Feb 29, 2024 | $644.4M | +29.1% | 54.5% | $197.0M | $137.5M |
| Dec 2022filed Mar 1, 2023 | $499.0M | +14.0% | 49.9% | $107.5M | $91.4M |
| Dec 2021filed Mar 11, 2022 | $437.8M | +25.1% | 45.6% | $69.9M | $62.1M |
| Dec 2020filed Mar 15, 2021 | $349.8M | +8.5% | 41.0% | $11.0M | $1.4M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched AMPH. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
4,333,767 shares short
-71,271 shares (-1.6%) vs Sep 30, 2026
13.8% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
4,405,038 shares short
-589,770 shares (-11.8%) vs Sep 15, 2026
14.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,994,808 shares short
-139,665 shares (-2.7%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
5,134,473 shares short
-250,766 shares (-4.7%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,385,239 shares short
+456,908 shares (+9.3%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,928,331 shares short
+753,871 shares (+18.1%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind AMPH’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if AMPH is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
20 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 23, 2026
Smart-money 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 1 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
211 filers reported a long position in AMPH for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
58.3%
of the 28.3M shares 13-F filers reported
Moves vs Q1 2026
6 added4 trimmed
Net shares held
+0.3%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $105.4M · 5.2M shares | 5.2M | -3.6% |
| 2 | DIMENSIONAL FUND ADVISORS LP | $46.5M · 2.3M shares | 2.3M | +13.7% |
| 3 | STATE STREET CORP | $33.1M · 1.6M shares | 1.6M | +2.2% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $29.9M · 1.5M shares | 1.5M | -4% |
| 5 | AMERICAN CENTURY COMPANIES INC | $23.7M · 1.2M shares | 1.2M | +15.6% |
| 6 | MARSHALL WACE, LLP | $21.5M · 1.1M shares | 1.1M | +4% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $19.6M · 969.8K shares | 969.8K | -0.7% |
| 8 | FULLER & THALER ASSET MANAGEMENT, INC. | $19.2M · 949.2K shares | 949.2K | -32% |
| 9 | D. E. Shaw & Co., Inc. | $17.9M · 887K shares | 887K | +33.3% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | $16.3M · 809.6K shares | 809.6K | +2.8% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of AMPH file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Jul 14, 2026 | DIMENSIONAL FUND ADVISORS LP13G · passive | 5.2% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for AMPH
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.